Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
OBJECTIVE
Our study was undertaken to evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and also its relationship with other hemostasis markers in a group of patients affected with polycystic ovary syndrome (PCOS)-under Diane-35 (ethinyl estradiol 0.035 mg/cyproterone acetate 2 mg) treatment or not-as compared with a group of healthy controls.


METHODS
Forty-two women with PCOS and 30 age-matched healthy controls were involved in the study. Group A were on Diane-35 for at least 6 months; group B did not take any drug; group C served as a control group.


RESULTS
TAFI antigen levels of groups A and B were significantly higher than in controls, but no difference was observed between them. All of the other coagulation and fibrinolysis parameters (including prothrombin time, activated partial thromboplastin time, fibrinogen and D-dimer) were comparable between the three groups.


CONCLUSIONS
The evidence presented herein suggests that women with PCOS have impaired fibrinolysis, as reflected by increased TAFI. This impairment can contribute to the risk of cardiovascular disease in PCOS. Elucidation of the modifiable mechanisms in PCOS can represent an opportunity for preventive therapy of the cardiovascular risks associated with PCOS.
Karakurt
Feridun
F
Department of Endocrinology, Fatih University Medical School, Ankara, Turkey. feridunkarakurt@yahoo.com
Gumus
Ilknur Inegol
II
Bavbek
Nuket
N
Kargili
Ayse
A
Koca
Cemile
C
Selcoki
Yusuf
Y
Ozbek
Mustafa
M
Kosar
Ali
A
Akcay
Ali
A
D000328:Adult; D000941:Antigens / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood*; D002318:Cardiovascular Diseases / Q000209:etiology; D016022:Case-Control Studies; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008954:Models, Biological; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D015854:Up-Regulation / Q000502:physiology; D055815:Young Adult
D000941:Antigens; D003278:Contraceptives, Oral, Hormonal; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D025901:Carboxypeptidase B2